NuMedii has been pioneering the use of Big Data, Artificial Intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs.
Enormous amounts of genomic, molecular and other biomedical data and knowledge pertaining to diseases and the behavior of drugs in various model systems are being generated and continue to expand exponentially. The key challenge is efficiently extracting meaning from these vast knowledge and data stores in a way that uncovers new therapeutic options for patients, particularly those who are diagnosed with cancer or rare diseases.
As a next generation biopharma company, NuMedii has built a powerful technology, AIDD (Artificial Intelligence for Drug Discovery) that harnesses Big Data and AI to rapidly discover connections between drugs and diseases at a systems level. We have efficiently extracted information from a vast array of disparate data stores to create a structured, proprietary data resource spanning hundreds of diseases and thousands of compounds. Our proprietary AI and machine learning algorithms enable us to extend well beyond conventional ‘target-centric’ drug discovery approaches by facilitating the exploration of favorable ‘poly-pharmacology’ profiles that can potentially improve therapeutic efficacy by modulating effects on multiple disease pathways.